Wed, Mar 4, 2015, 6:53 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

EnteroMedics Inc. Message Board

  • dctrig dctrig Apr 4, 2013 3:59 PM Flag

    Barrons Gives EnteroMedics $3.50 Price Target

    Bashers would have you sell in panic when you should be buying. Reality: sold and approved in Australia and Middle East, imminent filing in Europe and with FDA.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Monday 4/8 Barrons has ETRM @ 1.61 positive accumulation(1.0 being neutral). Don't forget that we are in the 2d qtr and ETRM has promised an FDA filing this quarter.

    • So, because Barrons gives etrm a 3.50/sh target, you gonna give me 3.50 share? I got over 27,000 shares I will sale you to-day. No? Now why not? Tell you what. How about you keep that pumping off this board and confined to that carrot in between your legs...

    • Barrons also told you ETRM was being "accumulated" a few days ago, and since then it's dropped about 15%.

      You remember touting about Barrons and "accumulation," don't you? How's that worked out for you this week?

    • It's amazing how folks forget that getting a medical device approved by the FDA is MUCH EASIER than a drug. The fall advisory panel will like VBLOC's great safety profile and ability to positively affect the evil trio of obesity, hypertension and diabetes.

      • 1 Reply to dctrig
      • A small miss in the trials BUT better than expected safety :

        The ReCharge Pivotal Trial of VBLOC Therapy is a prospective double-blind, sham-controlled clinical trial involving 239 randomized patients (233 implanted) at ten sites in the United States and Australia. Patients were surgically implanted with either a fully functional device with leads to the vagus nerve (treated) or a device without leads to the vagus nerve (sham control).

        In the primary analysis (intent-to-treat) population (n=239), treatment patients achieved a 24.4% average EWL compared to 15.9% for sham control patients. This 8.5% difference demonstrated statistical superiority over sham control (p=0.002), but not super-superiority at the pre-specified 10% margin (p=0.705). In total, 52.5% of treatment patients had 20% or more EWL compared to 32.5% in the control group (p=0.004), and 38.3% of treatment patients had 25% or more EWL compared to 23.4% in the sham control group (p=0.02). While the respective co-primary endpoint targets of 55% and 45% were not met, the endpoint targets were within the 95% confidence intervals for the observed rates and therefore the observed rates were not significantly lower than these pre-specified rates. These efficacy data demonstrate VBLOC Therapy's positive effect on weight loss.

        In the per protocol group, which included only those patients who received therapy per the trial design (n=211), the treatment patients had an average 26.3% EWL compared to 17.3% for the sham control group (p=0.003). In total, 56.8% of treated patients achieved at least 20% EWL, which was above the pre-defined threshold of 55%, compared to 35.4% in the sham control group (p=0.004). 41.8% of patients also achieved at least 25% EWL in this population, which is slightly less than the predefined threshold of 45%, compared to 26.2% in the sham control group (p=0.03).

        The rate of device-related serious adverse events was 3.1% for the treatment arm, significantly lower than the threshold .

1.13+0.03(+2.73%)Mar 4 3:59 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.